Author: claimsbot

1-17. (canceled)
18. A method for assembly of an electrical plug connector, with a plug connector housing, a printed circuit board, a first set of contact elements, a second set of contact elements, the first set of contact elements being arranged on a front face of the printed circuit board and projecting into an opening in the plug connector housing, the second set of contact elements being arranged on the rear face of the printed circuit board, the contact elements of the second set of contact elements being in the form of insulation-displacement contacts and a cable manager with a through-opening, the cable manager being formed on a front face with guides for wire cores which are intended to make contact with the insulation-displacement contacts, the guides in the region of the insulation-displacement contacts being formed with recessed holders for the insulation-displacement contacts, the cable manager being latchable to the plug connector housing, the method comprising the following method steps:
a) inserting the printed circuit board into the plug connector housing;
b) passing the cores of a cable with which contact is to be made through the openings in the cable manager from the rear face to the front face, with the cores being pressed into the associated guides and being cut off at the side edges;
c) aligning the cable manager with respect to the insulation-displacement contacts on the printed circuit board; and
d) pushing on a bracket-like tool, which has a guide edge complementary to an incline on the rear face of the cable manager and has a guide formed parallel to the plug connector housing so that the sliding movement is converted into a travel movement of the cable manager and plug connector housing toward one another, with the insulation displacement contacts making contact with the cores, and the plug connector and the cable manager being latched to one another.
19. A tool for assembly of a plug connector with a plug connector housing, a printed circuit board, a first set of contact elements, a second set of contact elements, the first set of contact elements being arranged on a front face of the printed circuit board and projecting into an opening in the plug connector housing, the second set of contact elements being arranged on the rear face of the printed circuit board, the contact elements of the second set of contact elements being in the form of insulation-displacement contacts and a cable manager with a through-opening, the cable manager being formed on a front face with guides for wire cores which are intended to make contact with the insulation-displacement contacts, the guides in the region of the insulation-displacement contacts being formed with recessed holders for the insulation-displacement contacts, the cable manager being latchable to the plug connector housing, the tool comprising:
an essentially U-shaped part with parallel-running guides arranged on a lower face of limbs, the guides pointing inward, and running at right angles to the rear wall of the tool and, in an upper region, the part having an obliquely running guide edge on the inside of each of the limbs.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes a polypeptide having haloperoxidase activity, wherein the polypeptide is selected from the group consisting of:
a) a polypeptide having an amino acid sequence which has at least 91% homology with the amino acid sequence of SEQ ID NO:2;
b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleotide sequence of SEQ ID NO:1, (ii) a subsequence of (i) of at least 100 nucleotides, or (iii) a complementary strand of (i) or (ii);
c) a variant of the polypeptide having an amino acid sequence of SEQ ID NO:2 comprising a substitution, deletion, andor insertion of one or more amino acids;
d) an allelic variant of (a) or (b);
e) a fragment of (a), (b), or (d) that has haloperoxidase activity; and
f) a polypeptide having more than 50% residual activity after 15 minutes incubation at 70 C. and pH 7.
2. The nucleic acid sequence of claim 1, wherein the amino acid sequence of the polypeptide has at least 95% homology with the amino acid sequence of SEQ ID No:2.
3. The nucleic acid sequence of any of claims 1-2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.
4. The nucleic acid sequence of any of claims 1-3, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2 or a fragment thereof.
5. The nucleic acid sequence of claim 4, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.
6. The nucleic acid sequence of claim 1, wherein the polypeptide is a variant of the polypeptide having an amino acid sequence of SEQ ID NO:2 comprising a substitution, deletion, andor insertion of one or more amino acids.
7. The nucleic acid sequence of claim 1, which is contained in the plasmid contained in E. coli DH10B, deposited as DSM 13441.
8. An isolated nucleic acid sequence comprising a nucleic acid sequence having at least one mutation in the polypeptide coding sequence of SEQ ID NO:1, in which the mutant nucleic acid sequence encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
10. A nucleic acid construct comprising the nucleic acid sequence of any of claims 1-7 operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host.
11. A recombinant expression vector comprising the nucleic acid construct of claim 10.
12. A recombinant host cell comprising the nucleic acid construct of claim 11.
13. A method for producing a mutant nucleic acid sequence, comprising (a) introducing at least one mutation into the polypeptide coding sequence of SEQ ID NO:1, wherein the mutant nucleic acid sequence encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2; and (b) recovering the mutant nucleic acid sequence.
14. A mutant nucleic acid sequence produced by the method of claim 13.
15. A method for producing a polypeptide, comprising (a) cultivating a strain comprising the mutant nucleic acid sequence of claim 14 encoding the polypeptide to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.
16. A method for producing the polypeptide of any of claims 1-7 comprising (a) cultivating a host cell comprising a nucleic acid construct comprising a nucleic acid sequence encoding the polypeptide under conditions suitable for production of the polypeptide; and (b) recovering the polypeptide.
17. A method for producing a polypeptide comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide, wherein the host cell comprises a mutant nucleic acid sequence having at least one mutation in the polypeptide coding sequence of SEQ ID NO:1, wherein the mutant nucleic acid sequence encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, and (b) recovering the polypeptide.
18. A method for shuffling of DNA comprising using the nucleotide sequence of SEQ ID NO:1.
19. A polynucleotide encoding a polypeptide having haloperoxidase activity obtainable by the method of claim 18.
20. A polypeptide having haloperoxidase activity encoded by the polynucleotide of claim 19.

What is claimed is:

1. A method for playing a card game between at least one player and a dealer using a deck of playing cards comprising:
each player making an ante wager;
the dealer dealing to each player five cards face down and dealing five cards to a dealer’s hand face down, each player examining their cards;
each player making a call wager or folding, each player folding losing their ante wager;
each player standing on their first five cards or paying an amount to receive up to two replacement cards for a like number of cards discarded from their hand;
revealing the dealer’s hand and (i) if the dealer’s hand does not have a predetermined qualifying holding paying each non-folded player even money on the ante wager and returning other wagers to the player (ii) if the dealer’s hand does have a qualifying holding and (ii) the player’s hand has a higher Poker hand ranking than the dealer’s (a) paying the player even money on the ante wager and paying the playing based upon a predetermined schedule of Poker rankings on the call wager and (iii) if the dealer’s hand outranks the player’s, collecting the player’s ante and call wagers.
2. The method of claim 1 comprising requiring each player to continue makes a call wager in the amount of twice the ante wager.
3. The method of claim 1 comprising paying the call wager according to one of the following rankings,
4
Call Bet Pay Schedule 1
Call Bet Pay Schedule 2
Final Hand Type
Pays (to 1)
Pays (to 1)
Pair of fives or
1
1
Better
Two Pair
2
2
Three of a Kind
5 to 2
5 to 2
(exception)
(exception)
Straight
3
3
Flush
5
4
Full House
6
6
Four of a Kind
20
20
Straight Flush
40
40
Royal Flush
100
100
4. The method of claim 1 comprising a player making a bonus wager and paying the playing a bonus if the player’s hand has a predetermined holding.
5. The method of claim 4 comprising paying said bonus wager based upon the holding of the player’s first dealt five cards.
6. The method of claim 4 comprising paying the player for the bonus wager according to one of the following schedule,
5
Bonus Payout Pay Table 1

Bonus Payout Pay Table 2
Hand Type
Pays ($)
Hand Type
Pays ($)
Straight
25
Straight
25
Flush
100
Flush
100
Full House
200
Full House
200
Four of Kind
500
Four of a Kind
500
Straight Flush
2,500
Straight Flush
2,000
Royal Flush
20,000
Royal Flush
10,000
7. The method of claim 1 comprising qualifying the dealer’s hand if it has a Poker ranking of a pair of 5s or better.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of reducing the increased blue and ultraviolet light damage to the retina of a subject having a condition that causes such blue or ultraviolet light to fall disproportionally on or in front of the retina relative to the blue and ultraviolet light damage present in a subject having no such condition, wherein the condition is presbyopia or hyperopia or astigmatism, comprising administering to the subject having such condition a composition comprising a therapeutically effective amount of one or more ocular antioxidants.
2. The method of claim 1, wherein said ocular antioxidant is selected from the group consisting of antioxidant vitamins, carotenoids, antioxidant minerals, natural antioxidant extracts and synthetic antioxidants.
3. The method of claim 2, wherein said antioxidant vitamin is selected from the list consisting of vitamins A, C, and E.
4. The method of claim 2, wherein said carotenoid is selected from the list consisting of lutein, zeaxanthin, beta-carotene, retinoids, retinal, retinaldehyde, and meso-zeaxanthin.
5. The method of claim 2, wherein said antioxidant mineral is selected from the list consisting of zinc, copper, and selenium.
6. The method of claim 2, wherein said natural extract is selected from the list consisting of polyphenols, quercitin, anthocyanins, and anthocyanidins.
7. The method of claim 2, wherein said synthetic antioxidant is selected from the list consisting of BHT, BHA, and BTHQ.
8. The method of claim 2, wherein said therapeutically effective amount of said antioxidant vitamin is between 0.02 (1 IU) and 15 mg (150 IU) per kilogram of body weight of said subject per day.
9. The method of claim 2, wherein said therapeutically effective amount of said carotenoid is between 0.0001 and 2 mg per kilogram of body weight of said subject per day.
10. The method of claim 2, wherein said therapeutically effective amount of said antioxidant mineral is between 0.0001 and 5 mg per kilogram of body weight of said subject per day.
11. The method of claim 2, wherein said therapeutically effective amount of said synthetic antioxidant is between 0.001 and 15 mg per kilogram of body weight of said subject per day.
12. The method of claim 2, wherein said therapeutically effective amount of said natural extract is between 0.0001 and 20 mg per kilogram of body weight of said subject per day.
13. The method of claim 2, wherein said therapeutically effective amount of said synthetic antioxidant is between 0.0001 and 20 mg per kilogram of body weight of said subject per day.